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PepducinsLipidated peptides (pepducins) can activate certain G-protein coupled receptors (GPCRs) through a unique
allosteric modulation mechanism involving cytosolic receptor domains. Pepducins with the amino acid se-
quence of the third intracellular loop of the neutrophil formyl peptide receptors (FPRs) as a common denom-
inator were N-terminally conjugated with palmitic acid. F2Pal16, containing the 16 amino acids present in the
third intracellular loop of FPR2, induced superoxide production in human neutrophils and the activity was
sensitive to FPR2 antagonists. Cells over-expressing FPR2 were similarly responsive and responded with a
transient increase in cytosolic calcium. No such effects were observed with the corresponding FPR1 pepducin.
The peptide alone, lacking palmitic acid, did not activate neutrophils. A ten amino acid long pepducin F2Pal10,
that was a more potent neutrophil activator than F2Pal16, was used for amino acid substitution studies. The
sequences of FPR1 and FPR2 in the third intracellular loop differ by only two amino acids, and a pepducin
with the FPR2-speciﬁc K231 replaced by the FPR1-speciﬁc Q231 lost all activity. The active F2Pal10 pepducin
also triggered a response in cells expressing a mutated FPR2 with the third intracellular loop identical to
that of FPR1. The data presented suggest that the same signaling pathways are activated when the signaling
cascade is initiated by a classical receptor agonist (outside-in signaling) and when signaling starts on the cy-
tosolic side of the membrane by a pepducin (inside-in signaling). A fundamental difference is also disclosed
between the two neutrophil FPRs regarding their sensitivities to third intracellular loop pepducins.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Lipidated peptides (pepducins) activate G-protein coupled recep-
tors (GPCRs) through a unique allosteric activation mechanism that in-
volves cytosolic parts of the receptor, but not the extracellular domains
typically used as binding sites for classical receptor agonists [1]. The
GPCRs represent a very large family of cell-surface receptors with
many common structural and functional characteristics. They all have
a conserved molecular structure with the N-terminus and C-terminus
exposed on different sides of the cell membrane which is transversed
seven times by the receptor peptide chain. From a functional point of
view, conventional agonists in the form of hormones, peptides, carbo-
hydrates, lipids, or large proteins interact with the extracellular loopsgy and Inﬂammation Research,
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l rights reserved.of the recognizing receptor as well as with transmembrane domains,
in regions localized closer to the cell surface. The agonist occupied re-
ceptor then transfers the primary signal to the G-protein binding struc-
tures present in the cytosolic part of the receptor [2]. The activated
receptor binds a heterotrimeric G-protein that when dissociated trans-
fers the signal further to different second messenger systems which
regulate functional responses of the cells expressing the receptor.
In contrast to conventional agonists, the activity of pepducins de-
pends on their capability to pass membranes and activate receptors
from the inside of cells [3]. In general, a pepducin comprises a short pep-
tide chain with an amino acid sequence identical to one of the intracel-
lular loops (typically the third) or the cytoplasmic tail of the receptor to
be targeted. The peptide is then N-terminally lipidated with a palmitoyl
group that acts as a hydrophobic anchor. Such an anchor is critical for
the ability of pepducins to gain access to the cell interior where they
supposedly activate signaling through an interaction with the cytosolic
parts of the receptor [1]. According to the predominant view regarding
themechanismof entrance, the palmitoyl groupbinds to themembrane
lipid bilayer allowing the peptide to “ﬂip” across the membrane and
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inside of a membrane exposing the right receptor, the peptide part of
the pepducin targets the interface between the receptor and the
G-protein and signaling is achieved through allosteric modulation.
This triggers a signal very similar to that induced by an agonist occupied
receptor. Accordingly the signal is transferred to the G-protein in the
case of an activating pepducin, whereas the “allosterism” induces a
block of the physical contact between the receptor and the G-protein
in the case of an antagonistic/inhibitory pepducin [4]. Several immune
regulatory GPCRs including the CXCR1, CXCR2 and CXCR4 have success-
fully been activated/inhibited by speciﬁc pepducins [5]. Recently the
Formyl Peptide Receptor 2 (FPR2) was added to the group of receptors
that can be activated by a pepducin [6,7].
The FPR2 belongs to the formyl peptide receptor (FPR) family of pat-
tern recognition receptors used by the innate immune system to sense
bacterial invasion as well as destructed tissues through the production/
release of N-formylated peptides, a unique hallmark of bacterial andmi-
tochondrialmetabolism [8]. The FPRs are exposed on cells that form our
ﬁrst line of defense against infection such as neutrophil granulocytes
and professional phagocytes of the monocyte/macrophage lineage [9].
Another family member, FPR1, for which an N-formylated methionyl
group is a critical determinant of ligand binding, is the best character-
ized receptor among all the neutrophil chemoattractant receptors.
Together with other receptors with similar functions such as the
C5a-receptor, the LTB4-receptor, and the PAF-receptor, the FPRs belong
to the larger family of G-protein coupled receptors (GPCRs) [10].
The two FPRs expressed on human neutrophils (FPR1 and FPR2)
have very similar primary sequences, but they bind and are activated
by different agonists [9]. For example, the prototypical bacterial
chemoattractant peptide fMLF starting with a formylated methionyl
group that is suggested to bind deep inside the receptor [11–13] is
recognized by FPR1 but not by FPR2. In contrast, certain peptides gen-
erated by community associated methillicin resistant Staphylococcus
aureus strains, starting with the same formylated amino acid, are spe-
ciﬁcally recognized by FPR2 rather than FPR1 [14,15]. Moreover, some
N-formylated peptides derived from mitochondrial protein synthesis
have been shown to be equally potent for FPR1 and FPR2. Some of
these are also low-afﬁnity agonists for FPR3 [8], the third family
member expressed in monocytes, which still lacks known, speciﬁc,
high afﬁnity agonists [16,17].
The precise biological roles of the FPRs are not completely under-
stood, but the identiﬁcation of both exogenous and endogenous li-
gands involved in inﬂammation strongly indicates a pivotal role of
these receptors in regulating inﬂammatory defense reactions [16].
FPR1 and FPR2 share a high degree of amino acid sequence similarity
particularly in the cytosolic (signal transducing) domains and the
functional repertoire induced by the two receptors is almost identical.
Despite these signaling similarities, there are some fundamental dif-
ferences between the two receptors. This is illustrated by the fact
that a gelsolin-derived phosphoinositol-binding peptide (PBP10)
speciﬁcally inhibits FPR2-triggered neutrophil activation [6,18,19].
Although the precise signal transduction step that is disrupted by
PBP10 remains to be elucidated, it is intriguing that the inhibitory ef-
fect of this peptide is, in contrast to the conventional antagonists, de-
pendent on its ability to pass membranes and the inhibitory effect is
thus likely to be mediated from the cytosolic side of the membrane,
a mechanism similar to that used by pepducins [3,20].
In this study we show that FPR2, but not FPR1, can be activated by
pepducins with amino acid sequences corresponding to the third in-
tracellular loop of the targeted receptor. The peptide alone (without
the lipid tail) did not activate the receptor and the signals induced
by the pepducins were indistinguishable from those induced by con-
ventional FPR2 agonists. The FPR2 pepducin-induced response was
inhibited by FPR2 speciﬁc antagonists, and on the receptor level,
sequences/regions apart from those in the third intracellular loop
appear to determine sensitivity to pepducins.2. Material and methods
2.1. Reagents
The chemoattractant fMLF, and isoluminol, superoxide dismutase
(SOD), as well as catalase were purchased from Sigma-Aldrich and the
horse radish peroxidase (HRP) was from Roche Diagnostics (Bromma,
Sweden). The chemoattractant WKYMVMwas synthesized and puriﬁed
by HPLC by Alta Bioscience (University of Birmingham, Birmingham,
United Kingdom). The pepducins and the non-palmitoylated control
peptidewith free termini aswell as the FPR2 speciﬁc gelsolin-derived in-
hibitory peptide PBP10 were synthesized by CASLO Laboratory (Lyngby,
Denmark). Pepducins were synthesized by Fmoc solid phase peptide
synthesis and N-terminal palmitoylation was made on the resin as the
last step before deprotection of side chains. Peptides were puriﬁed by
HPLC on a C18 column and the correct sequence of each peptidewas ver-
iﬁed byMALDI-TOFMass Spectrometry. All peptide stocks weremade in
DMSO and further dilutions were made in Krebs–Ringer phosphate
buffer containing glucose (10 mM), Ca2+ (1 mM) and Mg2+ (1.5 mM)
(KRG, pH 7.3). WRWWWW (WRW4) was from Genscript Corporation
(Scotch Plains, NJ, USA) and cyclosporin H was kindly provided by
Novartis Pharma (Basel, Switzerland). The FPR2 speciﬁc receptor antag-
onist Flipr, derived from S. aureuswas kindly provided by Dr JA van Strijp
(Utrecht, The Netherlands). Ficoll-Paque was obtained from Amersham
Biosciences. RPMI 1640, fetal calf serum (FCS), PEST and G418 were
from PAA Laboratories GmbH, Austria.2.2. Expression of formyl peptide receptors in HL-60 cells
The procedures used to obtain stable expression of FPR1 and FPR2 in
undifferentiated HL-60 cells have been previously described [21].
Control experiments with the speciﬁc agonists (fMLF for FPR1 and
WKYMVM for FPR2) were performed at each experimental event. The
wild type formof 3HA-tagged FPR2was purchased fromUMR cDNARe-
source Center, University of Missouri-Rolla. A mutant 3HA-tagged FPR
(3HA-FPR2loopR1) in which the sequence of the third intracellular
loop of FPR2 (KIHKKGMIKSSRPLRV) has been mutated to the sequence
of the third intracellular loop of FPR1 (KIHKQGLIKSSRPLRV) was creat-
ed by using the PCR strategy described by Yon and Fried [22]. Brieﬂy,
using 3HA-tagged FPR2 in pCDNA3.1 as a template, two intermediary
polymerase chain reaction fragments, PCR1 and PCR2, were generated
with two couples of primers. PCR1 was produced with a sense primer
that is located upstream the start codon. The 5′-end of the primer
contained an extension with an appropriate restriction site for further
ligation in an expression vector, whereas the reverse primer carried
the desired mutations. Likewise, PCR2 was created with a sense primer,
which is complementary to the reverse primer used for the synthesis of
PCR1, and a reverse primer, located downstream from the stop codon,
with an appropriate restriction site. After puriﬁcation, the two PCR frag-
mentsweremixed, denatured, and hybridized. Themixturewas used to
generate PCR3, which contains the mutated sequence. Ten cycles of
ampliﬁcation were ﬁrst performed in the absence of primers in order
to increase the number of copies of full length cDNA carrying themuta-
tions on both strands. Then, 35 cycles of ampliﬁcation were carried
out in the presence of the sense and reverse primers used to generate
PCR1 and PCR2. PCR3 was cleaved with the appropriate restriction en-
zymes for ligation in pCDNA3.1 (Invitrogen, Cergy Pontoise, France).
The entire sequence of the 3HA-tagged mutant was cloned in pEF-neo
for stable expression in HL-60 cells. The open reading framewas entire-
ly sequenced.
To prevent possible auto-differentiation due to the accumulation
of differentiation factors in the culture medium, cells were passed
twice a week before they reached a density of 2 × 106 cells/ml. At
each passage, an aliquot of the cell culture was centrifuged, the super-
natant was discarded and the cell pellet was resuspended in fresh
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(1 mg/ml).
2.3. Isolation of human neutrophils from peripheral blood
Blood neutrophils were isolated as described by Böyum [23] from
buffy coats from healthy volunteers. After dextran sedimentation at
1 ×g, hypotonic lysis of the remaining erythrocytes, the neutrophils
obtained by centrifugation in a Ficoll-Paque gradient were washed
twice in KRG. The cells were resuspended in KRG (1 × 107/ml) and
stored on ice until use.
2.4. Measurement of superoxide anion production
The production of superoxide anion by the neutrophil NADPH-
oxidase was measured by isoluminol-ampliﬁed chemiluminescence
(CL) in a six-channel Biolumat LB 9505 (Berthold Co, Wildblad,
Germany) as described earlier [24,25]. In short 2 × 105/ml neutro-
phils were mixed (in a total volume of 900 μl) with HRP (4 U), and
isoluminol (6 × 10−5 M) in KRG, pre-incubated at 37 °C after which
the stimulus (100 μl) was added. The isoluminol/HRP technique
detects the release of superoxide independent of H2O2 [24,25]. The
light emission was recorded continuously. When required, the
speciﬁc receptor inhibitors were included in the CL mixture forCB
A
Fig. 1. The pepducin F2Pal16 induces activation of the neutrophil superoxide generating NAD
receptor agonist, e.g., WKYMVM (right) interacting with a G-protein coupled receptor that
ceptor forms a signaling complex by association with the heterotrimeric G-protein. B): Prim
(solid line; 5 μM ﬁnal concentration) or an FPR1-derived F1Pal16 (dashed line; 5 μM ﬁnal co
activity was recorded continuously. For comparison, the neutrophil response induced by WK
of the agonists is indicated by arrows and a representative experiment out of more than ﬁ
arrow) of the pepducin F2Pal16 (solid line, 5 μM) and the F2Pal16 mutants F2Pal16K5 → Q (5 μ
was recorded continuously. One representative experiment out of ﬁve is shown. Abscissa, t5 min at 37 °C before stimulation. By a direct comparison of the
SOD inhibitable reduction of cytochrome C and SOD inhibitable
CL, 7.2 × 107 counts were found to correspond to a production of
1 nmol of superoxide (a millimolar extinction coefﬁcient cytochrome
C of 21.1 was used).
2.5. Determination of changes in cytosolic calcium
Cells were resuspended at a density of 2 × 107 cells/ml in KRG
containing 0.1 % BSA and loaded with 2 μM Fura 2-AM (Molecular
Probes, Eugene, OR) for 30 min, at room temperature. The cells were
then washed and resuspended in KRG at a density of 2 × 107 cells/ml.
The amount of cells used in the assay was 2 × 106 cells/measuring cu-
vette. Calcium measurements were carried out with a Perking Elmer
ﬂuorescence spectrophotometer (LS50) with excitation wavelengths
of 340 and 380 nm, and an emission wavelength of 509 nm. The tran-
sient rise in intracellular calcium is presented as ratio of ﬂuorescence
changes (340:380 nm) [26].
2.6. Determination of agonist binding by FACs analysis
To determine the effect of F2Pal10 on ligand binding to FPR2, a
Cy5-conjugated hexapeptide (Cy5-WKYMVM; 10−9 M ﬁnal concentra-
tion) was added to neutrophils stored on ice. The ﬂuorescent labeledPepducin F2Pal16
Agonist WKYMVM
Heterotrimeric G-protein
PH-oxidase. A): The mode of action of a pepducin, e.g., F2Pal16 (left) and a conventional
is transferred from a resting to a signaling state upon agonist binding. The activated re-
ary human neutrophils were activated by addition of an FPR2-derived pepducin F2Pal16
ncentration). The release of superoxide anions was used as the read out system and the
YMVM (100 nM ﬁnal concentration) is shown in the inset. The time point for addition
ve is shown. C): Primary human neutrophils were activated by addition (indicated by
M, dashed line), and F2Pal16M7 → L (dotted line, 5 μM). The release of superoxide anions
ime of study (min); ordinate, superoxide production in CPM × 10−6 (arbitrary units).
Fig. 2. The pepducin F2Pal16 desensitizes neutrophils to the FPR2 selective agonist
WKYMVM, but not to the FPR1 selective agonist fMLF. A): Primary human neutrophils
were ﬁrst activated by addition of the pepducin F2Pal16 (ﬁnal concentration 5 μM,
added at the long arrow) and when the response induced had declined, a second stimula-
tionwith FPR1 speciﬁc agonist fMLF (10 nMﬁnal concentration, added at the short arrow)
was received by the same batch of cells and the release of superoxide anions was contin-
uouslymeasured. The control neutrophils received fMLF only and the response induced is
shown (dashed line). B): Primary human neutrophils were ﬁrst activated by addition of
the pepducin F2Pal16 (ﬁnal concentration 5 μM, added at the long arrow) and when the
response induced had declined, a second stimulation with FPR2 speciﬁc agonist
WKYMVM (10 nM ﬁnal concentration, indicated by a short arrow) was received by the
same batch of cells and the release of superoxide anions was continuously measured.
The control neutrophils received WKYMVM only and the response induced is shown
(dashed line). A representative experiment out of more than ﬁve is shown. Abscissa,
time of study (min); ordinate, superoxide production in CPM × 10−6 (arbitrary units).
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F2Pal10 or non-labeled WKYMVM (10−7 M) and the cell/peptide mix-
tures were then incubated at 4 °C for 30 min. When the replacement
experiments were preformed, Cy5-WKYMVM was added to the cells
and bindingwas allowed to equilibrate at 4 °C for 45 min before the ad-
dition of F2Pal10 or non-labeledWKYMVM. The amounts of bound pep-
tides were determined as the mean ﬂuorescence intensity (MFI) using
an Accuri C6 ﬂow cytometer equipped with two laser lines (488 and
640 nm; Becton Dickinson Sparks, MD, USA).
2.7. Statistical analysis
One-way determinations of variance (ANOVA) were performed
for statistical analysis. A p value less than 0.05 was considered statis-
tically signiﬁcant.
3. Results
3.1. An FPR2 pepducin (F2Pal16; Pal- KIHKKGMIKSSRPLRV) with an
amino acid sequence identical to that of the third intracellular loop
of FPR2 activates primary human neutrophils
Membrane penetrating pepducins are suggested to target the inter-
face between the receptor and the signaling heterotrimeric G-protein
through some type of allosteric mimicking, and the same signal as
that induced by conventional agonists is transferred downstream of
the G-protein (Fig. 1A). We investigated the effect on neutrophils
of such a pepducin earlier identiﬁed through its ability to activate
monocytes, the F2Pal16 [7]. The amino acids in this peptide, F2Pal16
(Pal-KIHKKGMIKSSRPLRV), correspond to those present in the third in-
tracellular loop of FPR2 (spanning from K227 to V242). When exposed to
F2Pal16 primary human neutrophils responded with a robust respirato-
ry burst (Fig. 1B). The amount of released superoxide (O2−) increased
with increasing concentrations of the pepducin reaching a maximum
value at 5 μM. As compared to the classical FPR2 agonist WKYMVM,
the maximal amount of O2− release induced by F2Pal16 was lower but
the time course of the pepducin response was fairly similar to that in-
duced by WKYMVM (inset in Fig. 1B), reaching a peak value after
around a minute and then declined.
The amino acid sequence in the third intracellular loop of FPR1 is
almost identical to that in FPR2 and the difference is limited to two
amino acids. FPR1 contains a Q231 and an L233 corresponding to K231
and M233 in FPR2. Although very similar to F2Pal16 in amino acids,
the FPR1-pepducin Pal-KIHKQGLIKSSRPLRV (F1Pal16) was inactive
on primary neutrophils as no cell activity was induced by this peptide
(Fig. 1B). This shows a clear difference between FPR1 and FPR2 in that
only the latter receptor is susceptible to activation by a pepducin cor-
responding to its third intracellular loop.
To investigate the speciﬁc inﬂuence of the two differing amino acids,
we synthesized two FPR2–FPR1 “chimeric” pepducins, F2Pal16K5→ Q
(the FPR2 speciﬁc K231 was replaced with the FPR1 speciﬁc Q231) and
F2Pal16M7→ L (the FPR2 speciﬁc M233 was replaced with the FPR1 spe-
ciﬁc L233). Interestingly, the F2Pal16M7→ L was as active as the F2Pal16
peptide in inducing ROS release from neutorphils, while no activation
was induced by the F2Pal16K5→ Q (Fig. 1C).
3.2. F2Pal16 activates human neutrophils speciﬁcally through FPR2
Pepducins have been suggested to target the intracellular part of
the receptor from which its sequence is derived. Based on the fact
that FPR2 shares a large sequence homology with FPR1 in intracellu-
lar signaling domains, we next evaluated the receptor preference for
F2Pal16 using several different approaches. All results point to one
conclusion — FPR2 is the targeted receptor. Performing receptor de-
sensitization experiments using known FPR1 and FPR2 agonists we
found that neutrophils ﬁrst activated with F2Pal16 and then withthe FPR1 selective agonist fMLF were fully responsive to the second
challenge with fMLF (Fig. 2A). In contrast, F2Pal16 stimulated cells
were desensitized, i.e. non-responsive to the FPR2 selective agonist
WKYMVM (Fig. 2B). Thus, F2Pal16 desensitizes the cells to stimulation
with FPR2 agonist, but not to an FPR1 speciﬁc agonist. A preference
for FPR2 by F2Pal16 was conﬁrmed by the observation that a speciﬁc
FPR2 antagonist, theWRW4 peptide [27], inhibited the F2Pal16-induced
activity (Fig. 3). Inhibition was also demonstrated for FLIPr, an FPR2
speciﬁc antagonist from S. aureus [28] as well as the membrane perme-
able gelsolin-derived peptide PBP10 (Fig. 3). No inhibitory effect was,
however, obtainedwith cyclosporin H (Fig. 3), a potent FPR1 antagonist
[27].
The receptor preference of F2Pal16 for FPR2 was further conﬁrmed
using HL-60 cells stably expressing either FPR1 or FPR2. Stimulation
of cells over-expressing FPR2 with F2Pal16 induced a robust and tran-
sient increase in intracellular Ca2+ with a potency and a time-course
of the response similar to that induced by the speciﬁc FPR2 agonist
WKYMVM (Fig. 4A). No Ca2+ response was observed when FPR1
over-expressing cells were stimulated with F2Pal16, while these
cells responded well to the FPR1 speciﬁc agonist fMLF (Fig. 4B).
Taken together, our data conclusively show that the F2Pal16 is a po-
tent FPR2-speciﬁc neutrophil activator and that the signals generated
Fig. 3. The pepducin F2Pal16-induced response in primary neutrophils is inhibited by
FPR2 selective antagonists. Primary human neutrophils were activated by addition of
the pepducin F2Pal16 (ﬁnal concentration 5 μM) in the presence of the FPR2 antago-
nists PBP10 (1 μM), FLIPr (2.5 μg/ml) and WRW4 (5 μM) or the FPR1 antagonist
CysH (1 μM). The antagonists were allowed to interact with the cells for 5 min before
addition of F2Pal16 and the release of superoxide anions was continuously measured.
Data are expressed as percent superoxide production (peak values) compared to the
F2Pal16 induced in the absence of any antagonist (mean ± SEM, n = 3). The inset
shows a representative experiment out of ﬁve demonstrating a complete inhibition
by the FPR2 antagonist PBP10 (1 μM, dashed line) and lack of inhibition by the FPR1
antagonist CysH (1 μM, dotted line). Control neutrophils (solid line) were incubated
in the absence of antagonist. The time point for addition of F2Pal16 is indicated by an
arrow. Abscissa, time of study (min); ordinate, superoxide production in CPM × 10−6
(arbitrary units). ***p b 0.001; n.s. not signiﬁcant.
Fig. 4. The F2Pal16 pepducin induces a transient change in cytosolic calcium in cells
over-expressing FPR2. A): HL-60 cells over-expressing FPR2 were loaded with Fura-2
and the F2Pal16 peptide (0.25 μM ﬁnal concentration, solid line) was added to the
cells and the change of free cytosolic Ca2+ was monitored. The time point for addition
of F2Pal16 is indicated by an arrow. The Ca2+ response induced by the FPR2 speciﬁc ag-
onist WKYMVM (10 nM, dashed line) is included as a positive control. B): HL-60 cells
over-expressing FPR1 were loaded with Fura-2 and the F2Pal16 peptide (0.25 μM, solid
line) was added to the cells and the change of free cytosolic Ca2+ was monitored. The
time point for addition of F2Pal16 is indicated by an arrow. For comparison, the Ca2+
response induced by the FPR1 speciﬁc agonist fMLF (10 nM, dashed line) is included
as a positive control. Traces of representative calcium responses are shown and the ex-
periments have been performed at least three times. Abscissa, time of study (sec); or-
dinate, ﬂuorescence (arbitrary units).
Table 1
Peptide sequences of the different pepducins and the corresponding non-palmitoylated
peptides used in the study.
Peptide name Peptide sequence Peptide length
F1pal16 Pal-KIHKQGLIKSSRPLRV 16
F2pal16 Pal-KIHKKGMIKSSRPLRV 16
F2pal16K5 → Q Pal-KIHKQGMIKSSRPLRV 16
F2pal16M7 → L Pal-KIHKKGLIKSSRPLRV 16
F2pal8 Pal-KIHKKGMI 8
F2pal9 Pal-KIHKKGMIK 9
F2pal10 Pal-KIHKKGMIKS 10
F2pal10K5 → R Pal-KIHKRGMIKS 10
F2pal10K5 → N Pal-KIHKNGMIKS 10
F2pal10K5 → A Pal-KIHKAGMIKS 10
F2pal10K5 → Q Pal-KIHKQGMIKS 10
F2pal10K4 → Q Pal-KIHQKGMIKS 10
F1pal10Q5 → R Pal-KIHKRGLIKS 10
F210 KIHKKGMIKS 10
F2Lau10 Lau-KIHKKGMIKS 10
1918 H. Forsman et al. / Biochimica et Biophysica Acta 1833 (2013) 1914–1923by this pepducin are similar to those generated by conventional, ex-
tracellular FPR2 agonists.
3.3. Length, charge, and the presence of the palmitoyl group are important
determinants for FPR2 pepducin activity
Pepducin variants (listed in Table 1) with progressive C-terminal
truncations of F2Pal16 were designed, synthesized and, examined for
agonistic effect. There was an inverse relationship between pepducin
length and the activity down to 10 amino acids. Removal of one more
amino acid from F2Pal10, generating F2Pal9, resulted in a 50% loss of
potency (Fig. 5A). After removal of yet another amino acid, the
C-terminal lysine, generating F2Pal8, there was a complete loss of ac-
tivity (Fig. 5A). The F2Pal10 peptide was the most potent FPR2
pepducins examined with an EC50 value of 100 nM for activation of
the neutrophil NADPH-oxidase (Fig. 5B).
F2Pal10 peptides in which K5 (corresponding to K231 in the third
intracellular loop of FPR2) was exchanged for an N, A, or Q were inac-
tive as illustrated by their inability to trigger superoxide release from
primary human neutrophils (Fig. 6A) and the lack of Ca2+ responses
in FPR2 expressing HL-60 cells (shown for F2Pal10K5 → N in Fig. 6B).
These results are in total agreement with those described above for
the longer F2Pal16 pepducin (Fig. 1C). The peptide F2Pal10K5 → R in
which the K in position 5 corresponding to K231 in FPR2 was replaced
with the positively charged R retained the activity of F2Pal10
pepducin (Fig. 6). The importance of positive charge in position 5 in
mediating pepducin activity was further illustrated by the fact that
an FPR1-like pepducin (Pal-KIHKRGLIKS, F1Pal10Q5 → R) in which the
Q5 was substituted with the positively charged R, was as active as
the F2Pal10 peptide. It is also worth noting that, although the amino
acid sequence of F1Pal10Q5 → R differs from that of the third intracel-
lular loop of FPR2 in two positions and from that of FPR1 in only
one position, the activity was mediated exclusively through FPR2
(data not shown). In comparison to the K in position 5, the K in posi-
tion 4 is less important for activity, as a pepducin (F2Pal10K4 → Q) in
which K4 was replaced by a Q, was still active, although with a re-
duced potency (data not shown).
In accordance with the suggested mode of action of pepducins, re-
moval of the N-terminal palmitoyl group from F2Pal10 resulted in acomplete loss of activity even up to concentrations of 100 μM
(shown for 10 μM in Fig. 7A). An F2Lau10 peptide in which a lauryl
moiety (12 carbon atoms long) replaced the palmitoyl moiety (16
Fig. 5. The F2Pal10 and F2Pal9 pepducins trigger superoxide production from human
neutrophils. A): Neutrophils were activated with 0.6 μM (ﬁnal concentration) of
F2Pal10 and the C-terminal truncated peptides F2Pal9 and F2Pal8, and the release of su-
peroxide anions was continuously recorded. The time point for addition of the
pepducin is indicated by an arrow. A representative experiment out of more than
three is shown. Abscissa, time of study (min); ordinate, superoxide production in
CPM × 10−6 (arbitrary units). The inset shows the relative activity of F2Pal9 and
F2Pal8 expressed in percent of the peak value obtained by F2Pal10 (mean ± SEM,
n = 3). ***p b 0.001. B): Primary human neutrophils were activated by different con-
centrations of F2Pal10 and the production of superoxide recorded continuously is used
as the read out system. The concentration dependency is shown and the peak values
were used to calculate the percent of maximum release (100%) induced by F2Pal10 at
concentrations ≥0.3 μM. Abscissa, concentration of the pepducin; ordinate, peak
value of superoxide production (percent of max). The inset shows representative re-
sponses from the maximum release induced by 0.6 μM and a low response induced
by 0.04 μM F2Pal10. Inset; abscissa, time of study (min); ordinate, superoxide produc-
tion in CPM × 10−6 (arbitrary units).
Fig. 6. The F2Pal10K5- > R pepducin induces superoxide production in primary neutrophils
and a transient change in cytosolic calcium in cell over-expressing FPR2. A): Superoxide
production induced by the pepducin F2Pal10 mutants from primary human neutrophils
stimulated with F2Pal10 and F2Pal10 mutants F2Pal10K5→ R, F2Pal10K5→ N, F2Pal10K5→ A,
and F2Pal10K5→ Q (0.6 μM ﬁnal concentration for all peptides) and the release of superox-
ide was recorded continuously. Data were presented as relative superoxide production
comparing the peak values of the responses (percent of the response induced by
F2Pal10) (mean ± SEM, n = 3). B): Ca2+ responses induced by pepducin F2Pal10 and
peptide mutants in Fura-2 loaded HL-60 cells over-expressing FPR2. The pepducin
F2Pal10 (0.05 μM), F2Pal10K5→ R (0.05 μM) and F2Pal10K5→ N (1 μM) were added (indi-
cated by an arrow) and the change of free cytosolic Ca2+ was monitored by the Fura-2
ﬂuorescence. Traces of representative calcium responses are shown and the experiments
have been performed at least three times. Abscissa, time of study (sec); ordinate, ﬂuores-
cence (arbitrary units).
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was not as potent as the F2Pal10 pepducin (Fig. 7B).
In summary, these data suggest that the potent agonistic effect of
the F2Pal pepducin relies on the length of the fatty acid as well as the
length and charge of the peptide.3.4. F2Pal10 inhibits binding of the FPR2 agonist Cy5-WKYMVM to
neutrophils
In order to study the effect of F2Pal10 on agonist binding to FPR2, we
utilized the ﬂuorescently labeled agonist, Cy5-WKYMVM and quanti-
ﬁed binding/inhibition of binding to neutrophils by FACS-analysis. To
evaluate the binding of the ﬂuorescent Cy5-conjugated WKYMVM,
Cy5-WKYMVMwas allowed to bind in the absence or presence of an ex-
cess (100 times) of non-labeledWKYMVM. The non-labeledWKYMVM
largely inhibited the binding of the ﬂuorescent probe (Fig. 8A). The
binding of Cy5-WKYMVM was inhibited also by F2Pal10 in a dose-
dependent manner (Fig. 8B). The level of inhibition obtained with
1 μM of F2Pal10 was in the same range as that obtained with 100 nM
of WKYMVM (Fig. 8B inset).Using a replacement assay in which the Cy5-WKYMVM peptide
was allowed to interact with neutrophils for 45 min on ice prior to
the addition of non-labeled peptides, we could show that binding
was only modestly affected by an addition of excess of peptide
(F2Pal10 or WKYMVM) that was allowed to compete with the
Cy5-WKYMVM peptide (Fig. 8C).3.5. F2Pal10 activates a mutated FPR2 (FPR2K231M233 → QL)
The difference in primary sequence between the FPR1 and the FPR2
in the third intracellular loop is limited to two amino acids in positions
231 and 233. These two amino acids weremutated to give an FPR2mu-
tant (FPR2mut) that included the two FPR1-speciﬁc amino acids. When
expressed in HL-60 cells, this FPR2mut still recognized and responded
to the FPR2 speciﬁc agonist WKYMVM (not shown and [6]). The F2Pal
pepducin F2Pal10 triggered a response through FPR2mut (Fig. 9). The rel-
ative potency of the different F2Pal peptides did not differ between the
FPR2mut and the wild type FPR2 and no activity was induced in these
cells by the FPR1 pepducin F1Pal16 (data not shown). Taken together,
these data suggest that at the receptor level, sequences/regions apart
Fig. 7. The palmitoyl group is of importance for the F2Pal10 induced activity. A): The su-
peroxide production/release by primary human neutrophils following addition of the
pepducin F2Pal10 (0.3 μM ﬁnal concentration) or a non-palmitoylated variant with
the same peptide sequence F210 (10 μM ﬁnal concentration). The release of superoxide
anions was used as the read out system and the activity was recorded continuously.
The time point for addition of the peptides is indicated by an arrow and a representa-
tive experiment out of more than three is shown. Abscissa, time of study (min);
ordinate, superoxide production in CPM × 10−6 (arbitrary units). B): HL-60 cells
over-expressing FPR2 were activated by different concentrations (ﬁnal concentrations
from 0.05 to 1 μM) of the F2Lau10 pepducin containing a lauryl group as the hydropho-
bic anchor but with the same peptide sequence as F2Pal10. The change in intracellular
Ca2+ was monitored by the Fura-2 ﬂuorescence. F2Lau10 was added at the time point
indicated by an arrow. Traces of representative calcium responses are shown and the
experiments have been performed at least three times. Abscissa, time of study (sec);
ordinate, ﬂuorescence (arbitrary units).
+WKYMVM
- WKYMVM
N
um
be
r o
f n
eu
tro
ph
ils
N
um
be
r o
f n
eu
tro
ph
ils
Fluorescence
A
B
C
Fluorescence
+ 1 µM
- F2Pal10
+ 0.1 µM
+ 0.01 µM
1920 H. Forsman et al. / Biochimica et Biophysica Acta 1833 (2013) 1914–1923from those in the third intracellular loop may be involved in pepducin
sensitivity.Fig. 8. The F2Pal10 pepducin inhibits binding of the Cy5-WKYMVM peptide to neutro-
phils. A): The binding of Cy5-WKYMVM (1 nM ﬁnal concentration) to primary human
neutrophils was determined by ﬂow cytometry. Cells were incubated on melting ice
with the ﬂuorescently labeled Cy5-WKYMVM peptide in the absence (ﬁlled gray) or
in the presence of an excess of non-labeled WKYMVM (100 nM ﬁnal concentration,
solid line). The non-ﬂuorescent WKYMVM reduced binding and these values were de-
ﬁned as 100% inhibition. One representative histogram out of four is shown. B): The
binding of Cy5-WKYMVM (1 nM ﬁnal concentration) to primary human neutrophils
was determined by ﬂow cytometry. Cells were incubated on melting ice with the ﬂuo-
rescent labeled Cy5-WKYMVM peptide in the absence (ﬁlled gray) or in the presence
of different concentrations of F2Pal10 (ﬁnal concentrations 1 μM (solid line), 0.1 μM
(dotted line) and 0.01 μM (dashed line), respectively). At the highest concentration
of the F2Pal10 pepducin, binding of Cy5-WKYMVM was reduced to the same level as
by WKYMVM. The ﬁgure shows FACS curves from one representative experiment.
Inset: Inhibition of Cy5-WKYMVM binding to human neutrophils by 1 μM and
0.1 μM F2Pal10. Data are expressed as percent of the maximal inhibition obtained
with WKYMVM (100 nM ﬁnal concentration; mean ± SEM, n = 4). C): Cells were in-
cubated on ice for 45 min with Cy5-WKYMVM (1 nM ﬁnal concentration) prior to the
addition of WKYMVM (100 nM, gray bars) or F2Pal10 (1 μM, black bars) and the cell
associated ﬂuorescence was determined over time as indicated. Data are expressed
as percent of control (ﬂuorescence obtained in the absence of inhibitory peptides at in-
dicated time points) (mean ± SEM, n = 3).4. Discussion
Having the capacity to permeate cellmembranes, pepducins interact
with and control FPR2 mediated activities, thereby providing unique
tools for the regulation of innate immune related activities in human
neutrophils. The neutrophil activating pepducins described here have
amino acid sequences originating from the third intracellular loop of
FPR2 as a common denominator [6,7]. A pepducin with an amino acid
sequence corresponding to the same region of the closely related recep-
tor FPR1 lacked all activity ([6] and this study). A number of pepducins
targeting different GPCRs have been described. In contrast to conven-
tional agonists for GPCRs, cell-permeable pepducins exert their
receptor-mediated effects from inside the plasma membrane, but the
mechanism by which such peptides transduce intracellular signals in a
receptor selective/speciﬁc manner has not been clariﬁed in detail [1].
It is assumed that all pepducins act on the intracellular region of the
speciﬁcally targeted GPCR and induce their effects through a so-called
allosteric modulation of intracellular receptor domains that couple to
Cells over-expressing FPR2 K231M233 QL
Fig. 9. The F2Pal10 pepducin activates HL-60 cells over-expressing an FPR2mutant (FPR2-
mut). HL-60 cells stably expressing FPR2mut (FPR2K231M233→ Q231L233) were loaded with
Fura-2 and different concentrations (0.5 μM, solid line and 0.05 μM, dashed line) of the
F2Pal10 peptide was added to the cells and the change of free cytosolic Ca2+ was moni-
tored. The time point for addition of F2Pal16 is indicated by an arrow. The third intracellu-
lar loop of themutated FPR2 is identical to that of FPR1 and this was achieved through an
exchange of the two amino acids in the third intracellular loop that differ between the two
receptors. Traces of representative calcium responses are shown and the experiments
have been performed at least three times. Abscissa, time of study (sec); ordinate, ﬂuores-
cence (arbitrary units).
1921H. Forsman et al. / Biochimica et Biophysica Acta 1833 (2013) 1914–1923G-proteins and other signaling/regulating proteins [29]. Our data indi-
cate that there might be different, and possibly unique, modes of action
related to each individual pepducin/receptor pair.
It is believed that pepducins incorporate their lipid tail into the
phospholipid bilayer, enabling the peptide part of the construct to ﬂip
over the membrane and become exposed on the cytosolic side of the
membrane. This process has been termed ‘insertion and inversion’
[29]. Even though the precise mechanism has not been worked out at
the molecular level, the membrane binding and transport steps of the
pepducin technology are fairly easy to explain in physico-chemical
terms. It has been shown experimentally that pepducins may enter in-
tact cells [3], but since these experiments were performed at 37 °C on
functionally intact cells it is hard to determine if the intracellularly local-
ized peptides have just passed the membrane or are there as a result of
an endocytic uptake of receptor-ligand complexes. In order to be active,
the pepducins must have the ability to pass the plasma membrane, an
ability linked to the presence of the hydrophobic moiety (the palmitoyl
group). However, this does not conclusively prove that they initiate sig-
naling from the cell interior. To deﬁnitely prove that a pepducin triggers
its target receptor from the cytosolic side is a much more challenging
task than to merely show that the peptide can pass the membrane. Ba-
sically, several criteria should be fulﬁlled for the pepducin concept to be
valid, and one such criterion is that there should be a difference in activ-
ity between the fatty acid-linked and the non-lipidated peptide. This
criterion is fulﬁlled by the neutrophil F2Pal pepducins examined here.
Another criterion is that the pepducin should be able to trigger a re-
sponse in cells expressing the targeted receptor alone. This criterion is
also met for the activating F2Pal series of pepducins described here. It
should be noticed, however, that this criterion is valid also for classical
extracellular receptor speciﬁc agonists and is by no means a unique
property for pepducins.
With respect to the F2Pal series examined in this study, one criterion
usually fulﬁlled for other pepducins is not met; namely an insensitivity
to extracellular receptor antagonists. We determined the effects of
three different FPR2 selective antagonists, the WRW4 hexapeptide, the
bacterial peptide FLIPr, aswell as themembrane-permeable PBP10pep-
tide [27,30]. Our results conclusively demonstrate that F2Pal-induced
neutrophil activity induced by the FPR2 pepducins is blocked by the an-
tagonists. Since no detailed information regarding the pharmacological
characteristics of the FPR2 speciﬁc inhibitory peptides is available, themechanism can at this point not be clariﬁed. Our results may however
be explained without the necessity to abandon the pepducin concept,
if future studies show that the antagonists used have the same proper-
ties as earlier described FPR1 antagonists. These are either inverse ago-
nists rather than competitive neutral antagonists [31,32], or they trigger
a change of the receptor that affect the afﬁnity state and this change is
achieved without any G-protein coupling [33]. Binding to FPRs of
agonists aswell as antagonist induces an afﬁnity change of the occupied
receptor that is transferred from a low- to a high-afﬁnity state, and in-
terestingly enough this process occurs also at low temperatures (4 °C)
[33–35]. Induction of such an afﬁnity-switch could possibly explain
our binding data showing that F2Pal10 and WKYMVM inhibit binding
when added together with Cy5-WKYMVM but that these two peptides
basically lack effects when added to the ﬂuorescent probe occupied re-
ceptors. These data highlight the notion that the activation/inhibition
and modulation processes that regulate FPRs are very complex, and it
is intriguing that the inhibitory effects of an antagonist or an allosteric
modulator might require some type of cell/receptor activation that is
uncoupled from the G protein mediated signal transduction pathway
[33]. The precise mechanism of action of a given GPCR is determined
not only by the nature of the speciﬁc receptor but is also largely
inﬂuenced by the type of ligand examined, e.g., agonist, antagonist or
pepducins. Future studies should aim to clarify not only the precise
site (extracellularly or intracellularly) of action of FPR2 pepducins but
also whether binding of the known receptor antagonists induces this
type of G-protein independent receptor activation.
Inside the cell, the generally accepted model for how pepducins ac-
tivate signaling states that the peptide moiety of the molecule interacts
with the corresponding regions of the speciﬁcally targeted receptor ex-
posed on the inner leaﬂet of the membrane. This interaction is sug-
gested to lead to a stabilization of the receptor in an ‘activated’ state.
Our data on neutrophil activation by the F2Pal pepducins, indicate
that allosteric interaction with cytosolic receptor domains triggers the
same type of receptor dynamics and signaling as when the receptor is
activated by a conventional agonist that binds from the extracellular
side. In both cases signaling starts very rapidly after addition of the ac-
tivating compound, the peak of the response is reached at similar
times (after around a minute in terms of O2− production) and once sig-
naling has terminated the receptor is homologously desensitized.
The GPCR family members all have a similar seven transmem-
brane structure. Even though the initial pepducin strategy was to
use peptide sequences identical to the third intracellular loop of the
receptor to target this domain speciﬁcally, later work has shown
that pepducins can successfully be generated with amino acid se-
quences corresponding to any of the cytoplasmic receptor domains
[36]. The prevalent view regarding the mechanism for how a particu-
lar pepducin activates its target receptor is believed to be the stabili-
zation of the target GPCR in a particular conformational/signaling
state that involves an allosteric binding/modulation of that particular
part of the receptor fromwhich the peptide sequence of the pepducin
is derived. Accordingly, the activation induced by a pepducin with an
amino acid sequence corresponding to the third intracellular loop of
the targeted receptor should involve that particular part of that re-
ceptor [1]. However, how such activation is achieved is still unclear.
Although the two neutrophil receptors FPR1 and FPR2 are very
similar at the amino acid level, particularly in the cytoplasmic parts
of the receptors, no activity was induced by the F1Pal peptide, differ-
ing from the activating F2Pal molecule in only two amino acids. The
difference with respect to activity is actually related to one single
amino acid, corresponding to K231 of the receptor. The presence of
this FPR2-speciﬁc K in the pepducins appears to be critical for
pepducin activity. Pepducins in which K5 (corresponding to K231 in
the receptor) was replaced with a Q (the corresponding one in
FPR1), an A or an N do not activate FPR2, but when replaced by anoth-
er positively charged amino acid R the activity was retained. It is ob-
vious that the presence of a charged amino acid in position ﬁve of
1922 H. Forsman et al. / Biochimica et Biophysica Acta 1833 (2013) 1914–1923FPR2 pepducins is of major importance in receptor activation. Accord-
ingly, we found that when the non-charged Q5 in the F1Pal pepducin
was replaced with an R, this FPR1 like pepducin activated neutrophils,
but the receptor responsible for activation was FPR2, suggesting
a fundamental difference between the two receptors. Our earlier
study using PBP10 has clearly demonstrated that the two FPRs, al-
though eliciting very similar cellular responses, differ when it comes
to signaling [6]. It is important to notice that the FPR2 selective cell
permeable inhibitor PBP10 inhibits also the activity induced by
F2Pal pepducins. When the impact of the charge was further evaluat-
ed on the receptor level, we found that the response induced by
WKYMVM, in cells expressing the FPR2K231M233 → QL was intact,
suggesting that the charge alone does not change FPR2 signaling.
Moreover, this FPR1-like receptor mutant FPR2K231M233 → QL could
still be activated by F2Pal10, showing that there is no direct link be-
tween the amino acid sequence in the activating pepducin and that
of the receptor mediating the response. It remains to be determined
if the explanation to this at a molecular level is, that the third intracel-
lular loop is not directly involved in mediating the pepducin effect or
if a co-operation between different regions of the receptor is required.
Such a co-operation has been suggested to be of importance for the
activity of pepducins originating from protease activated receptors
[37].
The two human FPRs enable neutrophils to detect diverse agonists
derived from microbes or mitochondria, are structurally very similar
in their cytoplasmic signaling domains [9,16,38]. The third intracellu-
lar loop has been suggested to have an important role in signaling
transmitted by GPCRs including adrenergic and muscarinic receptors
[39]. No studies have been performed to identify the signaling regions
of FPR2, but with respect to FPR1, the use of receptor-mimetic pep-
tides has shown that a peptide spanning the third intracellular loop,
i.e., (K227 to P239) has no effect on binding to the G-protein,
suggesting that the third intracellular loop of alone is not important
for mediating G-protein coupling in FPR1 [40]. The data suggest in-
stead that membrane spanning extensions on both sides of the third
intracellular loop of are of importance G-protein binding [40]. These
regions that are very similar in FPR1 and FPR2, but even though noth-
ing is known about the structure-function relationship for FPR2, it is
reasonable to assume that intracellular signals generated by the two
FPRs rely on very similar structural changes when activated. The
fact that FPR2 but not FPR1 is susceptible to activation by pepducins
corresponding to the third cytoplasmic loop clearly implies that
there are signiﬁcant differences between these two closely related re-
ceptors. We have earlier disclosed one additional difference, namely
that a rhodamine-linked and membrane-permeable peptide inhibitor
(PBP10) selectively targets signaling from FPR2 [18,19]. This peptide
inhibits the F2Pal-induced neutrophil activation ([6] and this study)
suggesting that the two compounds (PBP10 and the F2Pal pepducin)
target the same signaling structure. We note that the peptide se-
quence in PBP10 has no sequence similarity with any regions in
FPR2. Whether PBP10 inhibits FPR2 signaling by competing with the
pepducin-like region for G-protein coupling or by the interaction
with other portions of the receptor remains to be determined.
Taken together the data presented here clearly show that the same
functional response and signaling pathways are activated when the sig-
naling cascade is initiated through agonists binding to the extracellular
domains of FPR2 (outside-in signaling), or when signaling starts through
an allosteric modulation of the receptor parts exposed on the cytosolic
side of themembrane (inside-in signaling). Our resultswith receptor an-
tagonists are not in agreement with the proposed allosteric modulation
mechanism for pepducins and the molecular background underlying
the antagonist sensitivity of F2Pal-induced activity has to be further in-
vestigated. Irrespective of the precisemechanism of pepducin activation,
we can now add one more fundamental difference to those earlier
described [16], between the two very closely related pattern recognition
receptors FPR1 and FPR2.Acknowledgements
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